International Journal of Endocrinology

International Journal of Endocrinology / 2014 / Article
Special Issue

Coordinating Care Aspects Related to Sexual Health in the Aging Male

View this Special Issue

Review Article | Open Access

Volume 2014 |Article ID 525249 |

Marcello Maggio, Francesca De Vita, Fulvio Lauretani, Antonio Nouvenne, Tiziana Meschi, Andrea Ticinesi, Ligia J. Dominguez, Mario Barbagallo, Elisabetta Dall’Aglio, Gian Paolo Ceda, "The Interplay between Magnesium and Testosterone in Modulating Physical Function in Men", International Journal of Endocrinology, vol. 2014, Article ID 525249, 9 pages, 2014.

The Interplay between Magnesium and Testosterone in Modulating Physical Function in Men

Academic Editor: Lorenzo Maria Donini
Received24 Nov 2013
Revised20 Jan 2014
Accepted20 Jan 2014
Published03 Mar 2014


The role of nutritional status as key factor of successful aging is very well recognized. Among the different mechanisms by which nutrients may exert their beneficial effects is the modulation of the hormonal anabolic milieu, which is significantly reduced with aging. Undernutrition and anabolic hormonal deficiency frequently coexist in older individuals determining an increased risk of mobility impairment and other adverse outcomes. Mineral assessment has received attention as an important determinant of physical performance. In particular, there is evidence that magnesium exerts a positive influence on anabolic hormonal status, including Testosterone, in men. In this review we summarize data from observational and intervention studies about the role of magnesium in Testosterone bioactivity and the potential underlying mechanisms of this relationship in male subjects. If larger studies will confirm these pivotal data, the combination of hormonal and mineral replacements might be adopted to prevent or delay the onset of disability in the elderly.

1. Biological Role of Magnesium

Magnesium is an essential ion involved in multiple fundamental physiologic functions in humans [1]. As part of the activated MgATP complex, magnesium is involved in the pathways generating adenosine triphosphate (ATP) and energy in mitochondria, electron transport chain and complex subunits, and oxygen detoxification. Magnesium is also a cofactor in over 300 enzymatic reactions and biological processes, including protein and nucleic acid synthesis, and neuromuscular excitability [1].

Circulating magnesium exists in three forms. The metabolically active free ionized fraction (magnesium ion) is the most represented, accounting up to 60–70% of the total serum magnesium. Other main serum forms include the protein-bound (25% and 8% bound to albumin and globulin, resp.) and the chelated magnesium fraction (12%) [2].

The most represented reservoir of magnesium in human body is the mineral phase of the bone that accounts for about 64% of total magnesium. The remaining amount is located in the intracellular (34%) and extracellular spaces (1%). The intracellular magnesium concentration is fundamental to ensure the most important cellular and metabolic activities [3]. Indeed, the rapid requirements of this cation are usually met by intracellular stores that more quickly exchange magnesium with intracellular fluids.

Because of the lack of clinical tests available for assessing total-body magnesium content, the serum magnesium concentration remains the most clinically reliable test.

Adequate serum magnesium levels (normal ranges: 0.75–0.95 mmol/L or 1.7–2.5 mg/dL) seem to be critical in ensuring the normal cellular homeostasis [1, 2]. Magnesium status is influenced by dietary intake, absorption in the gastrointestinal tract, renal excretion, and tissue uptake and utilization (e.g., cardiac and skeletal muscle tissue) [4]. To guarantee an optimal magnesium homeostasis the recommended intake from dietary sources is estimated in 420 and 320 mg/day for healthy men and women, respectively [5]. Food-rich magnesium sources are cereals, green leafy vegetables, seeds, nuts, cocoa, and seafood [6]. However, the definition of magnesium deficiency is notoriously complex. Magnesium serum concentrations below the laboratory reference range of <1.8 mg/dL are currently used to define some degree of magnesium depletion. However, this cut-off value could be not necessarily related to a pathophysiologic state of deficiency, because low intracellular magnesium has been documented even in patients with serum magnesium concentrations >1.8 mg/dL [7].

2. Magnesium and Muscle Function in Young Trained Individuals

Magnesium has been the most investigated mineral involved in muscle function. The beneficial effects of magnesium on skeletal muscle and physical performance are linked to its known actions on energetic metabolism (phosphorylation processes and reactions requiring ATP, energy utilization and transfer, and transmembrane transport) which have enormous implications in muscle contraction [1]. In fact, dietary magnesium deprivation is associated with increased oxygen requirements to complete submaximal exercise and reduced endurance performance [8].

Magnesium administration elicited the reductions in heart rate, ventilation, oxygen uptake, and carbon dioxide production during submaximal work [9, 10]. In male athletes, 25 days of magnesium (390 mg/d), with a 3 wk washout, increased peak oxygen uptake and total work output during work capacity tests [11]. Similarly, in physically active collegians, magnesium supplementation significantly improved endurance performance and oxygen utilization [12]. In a depletion-repletion experiment in 10 postmenopausal women (aged 45–71), dietary magnesium (320 versus 180 mg/d) improved magnesium balance, erythrocyte and skeletal muscle magnesium concentrations, heart rate, and oxygen consumption during submaximal exercise [13].

It is not surprising that most of the current observational and intervention studies have been conducted on athlete subjects. In young men participating at 7-week strength training program, supplemental magnesium was capable of significantly improving muscle strength and power [14]. The gain in muscle strength occurred at dietary magnesium intake higher than 250 mg/d and was even more evident at 500 mg/d (exceeding the recommended dietary allowance, RDA) [14]. However, magnesium supplementation per se does not affect work performance in magnesium-replete trained individuals [15]. Dietary surveys reveal a magnesium intake equaling or exceeding the RDA for male athletes [16]. In female athletes it tends to be 60% to 65% of the current recommendation. Regardless of sex, athletes competing in sports requiring weight classifications or esthetic components tend to consume up to 30–55% of the magnesium RDA [17]. Serum magnesium levels may also be reduced during intense and/or long-term exercise [18] leading to latent fatigue and decreased endurance [19], similarly to what has been observed during the condition of zinc deficiency [20].

These lines of evidence led to consider magnesium as potentially limiting element for human physical performance, creating the rationale for the routine use of magnesium supplementation during intense endurance exercise.

Suboptimal magnesium status is a frequent condition in older persons. The most common cause of magnesium deficit is the low dietary magnesium intake [21]. This is a well-represented phenomenon in older population, occurring in up to 10–15% of community-dwelling older subjects [22]. The typical western diet, highly rich in processed foods and deficient in green vegetables and whole grain, may also contribute to an inadequate magnesium intake.

The magnesium requirement for older population does not differ from young and adult subjects. However, data from the National Health and Nutrition Examination Survey (NHANES) III show an average daily magnesium intake dramatically below the recommended RDA, approximately of 225 mg/day in men and 166 mg/day in women [5].

A suboptimal magnesium status may also result from altered magnesium absorption and/or increased urinary loss [23]. Polypharmacotherapy (loop diuretics, digitals, and proton pump inhibitors) as well as a wide range of clinical conditions (HIV, type 2 diabetes, alcoholism, and cardiovascular diseases) plays additional important roles in lowering magnesium levels [2426].

However, the magnesium deficiency is more difficult to be detected in the elderly population. In fact the pauperization of intracellular stores is not usually accompanied by a parallel decline in magnesium serum concentrations that tend to remain more stable, within the normal range [27]. The deficiency of magnesium at cellular level and in the body stores is crucial for maintaining the skeletal muscle efficiency. It is very well known that sarcopenia (recently defined by consensus documents as the presence of both low muscle mass and low muscle function (strength or performance)) [2830] frequently leads to a condition of decreased physiological reserve, increased vulnerability to stressors, and adverse outcomes, known as “frailty” [31]. The frail status is a strong predictor of mortality, independent of traditional indicators of disease [32]. Despite the role of magnesium in muscle integrity and function, there are few data in this regard in the elderly. In a representative cohort of 1138 older men, Dominguez and colleagues [33] using data from the InCHIANTI Study showed a significant, independent, and strong positive relationship between circulating magnesium levels and measures of muscle performance (hand grip strength, lower-leg muscle power, knee extension torque, and ankle extension strength). These authors suggested the need of identifying serum magnesium cut-off values to attain the best possible physical function. These data suggest the potential contribution of low magnesium status, frequently observed in the elderly, to the reduced physical performance.

4. The Concept of Nutritional Modulation of Anabolic Hormonal Status in Older Men

In healthy adult subjects, changes in food consumption and utilization may induce homeostatic adaptations that redistribute nutrients without affecting muscle function and physical performance. During the aging process the body energy delivery system could be impaired because of the decline in physiological reserves and the disruption of metabolic pathways, and sarcopenia may arise. Physiological, psychological, and hormonal systems interact to determine the energy need. Macronutrients are essential to provide the body structure to perform work. Minerals are fundamental to enable the use of macronutrients for all physiological processes. In fact, an insufficient qualitative and quantitative nutrient intake is one of the multiple causes of loss of muscle mass, decreased physical performance, and adverse outcomes [34]. Anabolic hormones, whose levels decrease with age, play an important role in maintaining the optimal body energy delivery. In older persons, the occurrence of a single mild hormonal derangement is rarely observed. More frequently there is a simultaneous anabolic hormonal deficiency [Testosterone (T), Dehydroepiandrosterone (DHEA), estradiol (E2), growth hormone-Insulin-like Growth Factor-1 (GH-IGF-1), and vitamin D] which is part of “multiple hormonal dysregulation” [35]. These hormones interplay in ensuring overall anabolic state and induce the satellite cell activation together with exercise and muscle hypertrophy [35]. The simultaneous presence of low levels of Testosterone, together with DHEAS and IGF-1, has a strong effect on all-cause mortality in older men [36]. Experimental data confirm that hormonal therapies, singularly or in combination, may improve body composition and physical performance [3741]. The nutrients (especially the minerals magnesium, selenium, and zinc) and the anabolic hormones, especially T and IGF-1, seem to interact. The combination of nutritional and hormonal strategies in frail undernourished older people determines a more effective reduction in the number of hospitalizations, the time to hospital admission, and the days of hospital stay [42, 43]. The specific actions of both micronutrients and hormones at skeletal muscle level have led to the hypothesis of an interaction of these factors in ensuring optimal physical performance [44]. This novel concept could have important clinical implications in the elderly, who are more prone to a disruption of the anabolic/catabolic equilibrium and undernutrition. The use of specific mineral supplements may represent a sort of preventive measure of mobility impairment.

5. Changes in Testosterone Secretion with Age and Implications in Skeletal Muscle Function

Testosterone is the most important male sex steroid, synthesized by the Leydig cells of the testes (95%) and derived by peripheral adrenal androgens conversion for the remaining 5% [45].

In men, up to 44–65% of the circulating plasma T is bound to sex hormone binding globulin (SHBG) and 33–54% to albumin, and approximately 2-3% is available as a free form. The free fraction of circulating T plus albumin-bound T represents the amount of biologically active T (Bio-T) that more accurately reflects the clinical androgen state of the subject [46]. Total T levels progressively decrease from the age of 35, by 1% per year. The decline is more pronounced for Bio-T, 2% per year [45], especially in untreated depressed men [47, 48]. The causes of the age-related fall in total and Bio-T levels include a decrease in testicular function and a disruption of hypothalamic-pituitary axis. This peculiar phenomenon of the ageing process involves the GnRH secretion and activity (reduced amplitude of the peaks, attenuation of the circadian rhythm, and reduced sensitivity to negative feedback), the pituitary gland (reduced gonadotropin response to GnRH), and the Leydig cells (reduced response to human chorionic gonadotropin, HCG) [49].

Other mechanisms such as the increased SHBG levels and T aromatization (increased activity aromatase in adipose tissue) as well as the reduced bioconversion of T into dihydrotestosterone could also concur to impair T biological activity with age [50, 51]. Some authors hypothesize that the age-related decline in androgenic activity could be related to the reduced DHEA secretion, which is an important precursor of T [52]. Finally, qualitative changes in signaling transduction (reduced T receptors expression and/or impaired T binding capacity in the liver, brain, and prostate) should be also accounted for [53, 54].

The anabolic, anticatabolic, and neurotrophic effects of T administration on muscle are well known and extensively studied.

Observational studies on castrated animals [55] and adult men [56, 57] show that low T levels are associated with a reduction in lean body mass and muscle strength and other negative changes in body composition.

In a very recent cross-sectional analysis of 250 patients, 70 years or older, Ucak et al. [58] have found a negative impact of “compensated” or “subclinical” hypogonadism (defined as mild biochemical alterations accompanied by signs and symptoms of T deficiency) [59] on physical function, mood, cognitive, and nutritional status.

Intervention studies on elderly subjects have documented beneficial effects of T on counteracting the age-related changes of body composition and physical function [6062]. T exerts direct influence on lean body mass and strength [63, 64], whereas equivocal evidence is available on the effects of T on physical performance and quality of life [35].

The anabolic effects of T are even more evident in older subjects with mobility limitation.

In 209 community-dwelling men with low T levels (100 to 350 ng/dL [3.5 to 12.1 nmol/L]) from Testosterone in Older Men (TOM) with Mobility Limitations Trial, the daily T gel therapy for 6 months improved both leg-press and chest-press strength and stair-climbing power [65]. Testosterone may also influence muscle metabolism by improving haemoglobin levels in older men with mild anaemia [66, 67]. In women, skeletal muscle tissue seems to be sensitive to the anabolic action of androgens [68]. However, the impact of T administration on full physical function has not been fully studied. The precise molecular mechanisms underlying these observed physical changes in men are likely to include specific T effects on adipocytes and skeletal muscle cell receptors. The binding of T to its receptors could lead to the stimulation of lipolysis and protein synthesis [41, 69]. Finally, several lines of evidence support the hypothesis of permissive effects of T on the differentiation of the precursor stromal cells into muscular line [70].

6. The Interplay between Magnesium and Testosterone in Physical Function

The hypothesis of a link between magnesium and T has been tested in pivotal experiences using magnesium supplementation in adult subjects. Brilla and Conte investigated the combined role of magnesium supplementation and exercise on T levels [71]. A simple zinc-magnesium nutritional formulation (30 mg zinc monomethionine aspartate, 450 mg magnesium aspartate, and 10.5 mg of vitamin B-6) was able to improve T levels of athletes engaging in intense physical activity compared to placebo (132.1 to 176.3 pg/mL versus 141 to 126.6 pg/mL). The highest levels of T were found in those athletes both exercising and receiving magnesium supplementation. Moreover, significant differences in muscle strength via torque measurements and functional power were noted between the 2 groups (189.9 to 211 Nm at 180°/s and 316.5 to 373.7 Nm at 300°/s versus 204.2 to 209.1 Nm at 180°/s and 369.5 to 404.3 Nm at 300°/s). These data have been confirmed in a recent study performed on young subjects, where 4-week magnesium supplementation (magnesium sulfate 10 mg/kg/d) and exercise increase free and total T concentrations at exhaustion before and after supplementation compared to resting levels [72, 73]. There are limited data about the relationship between magnesium and T in study population, especially of older subjects. Maggio and colleagues [74] in 399 older men ≥ 65 years ( mean age ± SD) from the InCHIANTI Study documented for the first time the strong and positive association between magnesium levels and total T and total IGF-1 levels. Interestingly, the relationship between magnesium and T was independent of body mass index, IL-6, DHEAS, SHBG, insulin, total IGF-1, grip strength, Parkinson’s disease, and chronic heart failure. Because of the cross-sectional nature of the study the authors could not establish a cause-effect relationship between magnesium and T levels. This finding led the authors to perform a pilot single-center, randomized, placebo-controlled, single-blind intervention study. 46 elderly hospitalized male subjects (21 in the treatment group), aged 65 years or older, with magnesium serum levels < 2.5 mg/dL, were randomly assigned to magnesium sulfate treatment (1 g/mL of ion Mg++ diluted in 250 cc of normal saline solution) or placebo (250 cc of saline solution) [75]. The active product or placebo was in a single intravenous dose administered in about 30 minutes. Testosterone, IGF-1, SHBG, and C-reactive protein (CRP) concentrations were evaluated before and after treatment. All measurements were performed at the Laboratory of the University-Hospital of Parma. Baseline characteristics between intervention and control groups were analyzed by -test. Paired -test was used to examine and to compare the response trends between the two groups at baseline and after treatment. As expected, magnesium sulfate administration induced a significant increase in serum magnesium levels (delta ) compared to placebo (delta ) (). Interestingly, total T levels remained substantially unchanged (delta ) in the intervention group while they were significantly decreased in the placebo group (delta ). The difference in total T levels between the 2 groups touched the statistical significance () (Figure 1). No differences were appreciated in bioavailable T (Bio-T), IGF-1, and SHBG concentrations. In this preliminary analysis no differences in CRP levels were observed between the two groups at baseline. The adjustment for CRP levels at baseline did not affect the relationship between magnesium and total T [75].

These preliminary data in humans are supported by experimental studies in animal models.

Interestingly, magnesium supplementation has been shown to have an apparent beneficial effect on male gonadal system, as observed in a very recent study performed on sexually mature male rats [76]. Chandra et al. evaluated the morphological, cytological, and functional changes in testis after magnesium administration. Interestingly, the authors showed significant enhancing in steroidogenic enzymes, namely, delta(5)3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase, activities at moderate and high dose of magnesium that resulted in increased serum T levels [76]. This phenomenon was followed by a progressive development in cytoarchitecture of genital organs without significant changes in quantitative spermatogenesis. The results were remarkably more evident in the groups treated for a longer period and at high doses of magnesium. In mice, dietary magnesium depletion seems to target apical cells within caput epididymis [77]. Moreover, in older male dromedary camel, the age-related decline in plasma T concentrations has been associated with a disruption of the mechanisms controlling normal cation distribution (including magnesium) in the testis, epididymis, and accessory glands [78].

7. The Role of Inflammation in the Interplay between Magnesium and Testosterone Levels

We can account for different factors influencing both T and magnesium concentration in adult and elderly men. Particular attention deserves the role of inflammation, which is a negative modulator of both these factors.

Inflammatory cytokines act as inhibitory factors at pituitary (on the secretion of LH) and testicular level (reduction of T secretion and sensitivity of T to LH) [79], contributing to the development of hypogonadism.

Higher levels of inflammatory markers and low T concentration are strong predictors of frailty, disability, and cardiovascular events [80, 81] that negatively influence the muscle mass [82].

In older men, there is a steeper decline of T levels during a proinflammatory postoperative status (also known as “acute postoperative frailty”) [83].

However, short-term T administration seems in turn to reduce systemic inflammatory cytokines including TNF-alpha, IL-6, and IL-1β [84] and to increase the anti-inflammatory cytokine IL-10 [85]. In a similar manner, magnesium seems to be fundamental in maintaining the threshold of antioxidant capacity and the control of oxidative stress [1]. Moreover, there is evidence of impaired overall antioxidant capacity and low-grade inflammation in magnesium-deficient cultured human and animals cells [86]. Inadequate intracellular magnesium may reduce the mitochondrial efficiency and increase the production of reactive oxygen species (ROS), determining structural and functional impairment of proteins [87] and DNA [88]. Interestingly, magnesium and T were found to be lower during systemic inflammation, and conditions associated with both increased ROS, oxygen-derived free radicals, oxygen peroxide production, and impaired antioxidant enzyme expression and activity [89, 90].

Multiple changes in physiological pathways could be identified as pathogenic factors in several age-related phenomena including sarcopenia, frailty, disability, or altered immune response and chronic diseases. Therefore, during the aging process, where lower anabolic hormones, increased proinflammatory cytokines, and impaired nutritional status frequently coexist, combined strategies could have important clinical implications [91] (Figure 2).

8. Biomolecular Mechanisms Underlying the Relationship between Magnesium and Testosterone

In the recent years biomolecular interactions between T, SHBG, and magnesium have been studied by high performance liquid chromatography (HPLC) [92]. Excoffon and colleagues [92] provided evidence of a magnesium-mediated variation in the T-SHBG affinity. The change in magnesium levels inside the biological serum concentration range (0.75–0.95 mM) could lead to an enhancement of the Bio-T. In fact, the affinity of T to SHBG seems to change slightly with the magnesium concentration. Magnesium binds SHBG in a nonspecific mode, leading to an uncompetitive inhibition with T in binding SHBG and to a subsequent enhancement of Bio-T availability. The binding is accompanied by a magnesium release (or uptake) with a corresponding heat effect around in magnitude 17 kJ/mol [92].

SHBG is a homodimer comprising 373 amino acid residues for each monomer that transports the sex steroids in the blood and also regulating their activity in target cells [93]. Interestingly, each monomer of SHBG contains three metal-binding sites, one calcium-binding and two zinc-binding, [94, 95], that are divalent cations as well as magnesium. This data supports, at molecular level, the role of magnesium in modulating T bioactivity.

Guillaume’s group investigated the role of magnesium on both the T-serum albumin binding process and the T displacement to its human serum albumin (HSA) binding cavity by DHEA. Serum albumin binds to T with low affinity [46]. In particular DHEA and T seem to bind to the same HSA site. DHEA has been shown to displace T to its HSA binding site. The authors observed in vitro that adequate magnesium concentrations displaced T from its HSA binding site [96, 97] and hypothesized the opportunity of testing in vivo the effects of magnesium supplementation, during DHEA treatment, on the Bio-T rate.

9. Conclusions

The ageing process seems to be at least partly due to the defect of anabolic hormones, low-grade inflammation, reduced physical activity, and a poor quality of nutrition.The permissive role that several micronutrients, such as magnesium, might exert on the serum concentration and the biological activity of T could be of undoubted interest for future clinical approaches. Male individuals with impaired magnesium status and T deficiency (accurately assessed) could benefit from magnesium and/or T treatment targeting physical performance. Future randomized clinical trials adopting synergistic treatments could lead to improving the effectiveness of T treatment, in preventing mobility limitation and adverse outcomes in older men.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. M. Barbagallo and L. J. Dominguez, “Magnesium and aging,” Current Pharmaceutical Design, vol. 16, no. 7, pp. 832–839, 2010. View at: Publisher Site | Google Scholar
  2. N.-E. Saris, E. Mervaala, H. Karppanen, J. A. Khawaja, and A. Lewenstam, “Magnesium: an update on physiological, clinical and analytical aspects,” Clinica Chimica Acta, vol. 294, no. 1-2, pp. 1–26, 2000. View at: Publisher Site | Google Scholar
  3. R. A. Reinhart, “Magnesium metabolism: a review with special reference to the relationship between intracellular content and serum levels,” Archives of Internal Medicine, vol. 148, no. 11, pp. 2415–2420, 1988. View at: Publisher Site | Google Scholar
  4. F. I. Wolf and A. Cittadini, “Chemistry and biochemistry of magnesium,” Molecular Aspects of Medicine, vol. 24, no. 1–3, pp. 3–9, 2003. View at: Publisher Site | Google Scholar
  5. E. S. Ford and A. H. Mokdad, “Dietary magnesium intake in a national sample of US adults,” The Journal of Nutrition, vol. 133, no. 9, pp. 2879–2882, 2003. View at: Google Scholar
  6. J. R. Marier, “Magnesium content of the food supply in the modern-day world,” Magnesium, vol. 5, no. 1, pp. 1–8, 1986. View at: Google Scholar
  7. R. K. Rude, A. Stephen, and J. Nadler, “Determination of red blood cell intracellular free magnesium by nuclear magnetic resonance as an assessment of magnesium depletion,” Magnesium and Trace Elements, vol. 10, no. 2–4, pp. 117–121, 1991. View at: Google Scholar
  8. H. C. Lukaski, “Vitamin and mineral status: effects on physical performance,” Nutrition, vol. 20, no. 7-8, pp. 632–644, 2004. View at: Publisher Site | Google Scholar
  9. S. W. Golf, S. Bender, and J. Grüttner, “On the significance of magnesium in extreme physical stress,” Cardiovascular Drugs and Therapy, vol. 12, no. 2, pp. 197–202, 1998. View at: Publisher Site | Google Scholar
  10. L. Vecchiet, G. Pieralisi, M. L. D’Ovidio et al., “Effects of magnesium supplementation on maximal and submaximal effort,” in Magnesium and Physical Activity, L. Vecchiet, Ed., pp. 227–237, Parthenon, London, UK, 1995. View at: Google Scholar
  11. R. K. Rude, “Magnesium metabolism and deficiency,” Endocrinology and Metabolism Clinics of North America, vol. 22, no. 2, pp. 377–395, 1993. View at: Google Scholar
  12. L. R. Brilla and K. B. Gunther, “Effect of magnesium supplementation on exercise time to exhaustion,” Medicine, Exercise, Nutrition and Health, vol. 4, pp. 230–233, 1995. View at: Google Scholar
  13. H. C. Lukaski and F. H. Nielsen, “Dietary magnesium depletion affects metabolic responses during submaximal exercise in postmenopausal women,” The Journal of Nutrition, vol. 132, no. 5, pp. 930–935, 2002. View at: Google Scholar
  14. S. Terblanche, T. D. Noakes, S. C. Dennis, D. Marais, and M. Eckert, “Failure of magnesium supplementation to influence marathon running performance or recovery in magnesium-replete subjects,” International Journal of Sport Nutrition, vol. 2, no. 2, pp. 154–164, 1992. View at: Google Scholar
  15. L. R. Brilla and T. F. Haley, “Effect of magnesium supplementation on strength training in humans,” Journal of the American College of Nutrition, vol. 11, no. 3, pp. 326–329, 1992. View at: Google Scholar
  16. H. C. Lukaski, “Prevention and treatment of magnesium deficiency in athletes,” in Magnesium and Physical Activity, L. Vecchiet, Ed., pp. 211–226, Parthenon, London, UK, 1995. View at: Google Scholar
  17. J. F. Hickson Jr., J. Schrader, and L. C. Trischler, “Dietary intakes of female basketball and gymnastics athletes,” Journal of the American Dietetic Association, vol. 86, no. 2, pp. 251–253, 1986. View at: Google Scholar
  18. A. L. Buchman, C. Keen, J. Commisso et al., “The effect of a marathon run on plasma and urine mineral and metal concentrations,” Journal of the American College of Nutrition, vol. 17, no. 2, pp. 124–127, 1998. View at: Google Scholar
  19. L. R. Brilla and V. P. Lombardi, “Magnesium in sports physiology and performance,” in Sports Nutrition: Minerals and Electrolytes. An American Chemical Society Monograph, C. V. Kies and J. A. Driskell, Eds., pp. 139–177, CRC Press, Boca Raton, Fla, USA, 1995. View at: Google Scholar
  20. A. Córdova and F. J. Navas, “Effect of training on zinc metabolism: changes in serum and sweat zinc concentrations in sportsmen,” Annals of Nutrition & Metabolism, vol. 42, no. 5, pp. 274–282, 1998. View at: Publisher Site | Google Scholar
  21. Y. N. Berner, F. Stern, Z. Polyak, and Y. Dror, “Dietary intake analysis in institutionalized elderly: a focus on nutrient density,” The Journal of Nutrition, Health and Aging, vol. 6, no. 4, pp. 237–242, 2002. View at: Google Scholar
  22. J. E. Morley, “Anorexia of aging: physiologic and pathologic,” The American Journal of Clinical Nutrition, vol. 66, no. 4, pp. 760–763, 1997. View at: Google Scholar
  23. M. Barbagallo, M. Belvedere, and L. J. Dominguez, “Magnesium homeostasis and aging,” Magnesium Research, vol. 22, no. 4, pp. 235–246, 2009. View at: Publisher Site | Google Scholar
  24. A. L. Lameris, L. A. Monnens, R. J. Bindels, and J. G. Hoenderop, “Drug-induced alterations in Mg2+ homoeostasis,” Clinical Science, vol. 123, no. 1, pp. 1–14, 2012. View at: Publisher Site | Google Scholar
  25. T. Cundy and A. Dissanayake, “Severe hypomagnesaemia in long-term users of proton-pump inhibitors,” Clinical Endocrinology, vol. 69, no. 2, pp. 338–341, 2008. View at: Publisher Site | Google Scholar
  26. E. J. Hoorn, J. van der Hoek, R. A. de Man, E. J. Kuipers, C. Bolwerk, and R. Zietse, “A case series of proton pump inhibitor-induced hypomagnesemia,” American Journal of Kidney Diseases, vol. 56, no. 1, pp. 112–116, 2010. View at: Publisher Site | Google Scholar
  27. M. Barbagallo, R. K. Gupta, L. J. Dominguez, and L. M. Resnick, “Cellular ionic alterations with age: relation to hypertension and diabetes,” Journal of the American Geriatrics Society, vol. 48, no. 9, pp. 1111–1116, 2000. View at: Google Scholar
  28. A. J. Cruz-Jentoft, J. P. Baeyens, J. M. Bauer et al., “Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People,” Age and Ageing, vol. 39, no. 4, pp. 412–423, 2010. View at: Publisher Site | Google Scholar
  29. I. H. Rosenberg, “Sarcopenia: origins and clinical relevance,” The Journal of Nutrition, vol. 127, no. 5, pp. 990S–991S, 1997. View at: Google Scholar
  30. M. Muscaritoli, S. D. Anker, J. Argilés et al., “Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and ‘nutrition in geriatrics’,” Clinical Nutrition, vol. 29, no. 2, pp. 154–159, 2010. View at: Publisher Site | Google Scholar
  31. J. E. Morley, B. Vellas, G. A. van Kan et al., “Frailty consensus: a call to action,” Journal of the American Medical Directors Association, vol. 14, no. 6, pp. 392–397, 2013. View at: Publisher Site | Google Scholar
  32. S. A. Bridenbaugh and R. W. Kressig, “Quantitative gait disturbances in older adults with cognitive impairments,” Current Pharmaceutical Design, 2013. View at: Publisher Site | Google Scholar
  33. L. J. Dominguez, M. Barbagallo, F. Lauretani et al., “Magnesium and muscle performance in older persons: the InCHIANTI study,” The American Journal of Clinical Nutrition, vol. 84, no. 2, pp. 419–426, 2006. View at: Google Scholar
  34. T. Cederholm, A. Nouvenne, A. Ticinesi et al., “The role of malnutrition in older persons with mobility limitations,” Current Pharmaceutical Design, 2013. View at: Publisher Site | Google Scholar
  35. M. Maggio, F. Lauretani, F. de Vita et al., “Multiple hormonal dysregulation as determinant of low physical performance and mobility in older persons,” Current Pharmaceutical Design, 2013. View at: Publisher Site | Google Scholar
  36. M. Maggio, F. Lauretani, G. P. Ceda et al., “Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the chianti area (InCHIANTI) study,” Archives of Internal Medicine, vol. 167, no. 20, pp. 2249–2254, 2007. View at: Publisher Site | Google Scholar
  37. K. T. Brill, A. L. Weltman, A. Gentili et al., “Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 12, pp. 5649–5657, 2002. View at: Publisher Site | Google Scholar
  38. O. Ragnarsson, M. G. Burt, K. K. Ho, and G. Johannsson, “Effect of short-term GH and testosterone administration on body composition and glucose homoeostasis in men receiving chronic glucocorticoid therapy,” European Journal of Endocrinolgy, vol. 168, no. 2, pp. 243–251, 2013. View at: Publisher Site | Google Scholar
  39. K. Nimptsch, E. A. Platz, W. C. Willett, and E. Giovannucci, “Association between plasma 25-OH vitamin D and testosterone levels in men,” Clinical Endocrinology, vol. 77, no. 1, pp. 106–112, 2012. View at: Publisher Site | Google Scholar
  40. F. Sattler, S. Bhasin, J. He et al., “Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial,” The Journals of Gerontology A, vol. 66, no. 1, pp. 122–129, 2011. View at: Publisher Site | Google Scholar
  41. R. J. Urban, Y. H. Bodenburg, C. Gilkison et al., “Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis,” American Journal of Physiology, vol. 269, no. 5, pp. E820–E826, 1995. View at: Google Scholar
  42. I. M. Chapman, R. Visvanathan, A. J. Hammond et al., “Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women,” The American Journal of Clinical Nutrition, vol. 89, no. 3, pp. 880–889, 2009. View at: Publisher Site | Google Scholar
  43. C. Piantadosi, R. Visvanathan, V. Naganathan et al., “The effect of testosterone and a nutritional supplement on hospital admissions in under-nourished, older people,” BMC Geriatrics, vol. 11, article 66, 2011. View at: Publisher Site | Google Scholar
  44. M. Maggio, F. De Vita, F. Lauretani et al., “IGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty,” Nutrients, vol. 5, no. 10, pp. 4184–4205, 2013. View at: Publisher Site | Google Scholar
  45. R. Arianayagam, M. Arianayagam, S. McGrath, and P. Rashid, “Androgen deficiency in the aging man,” Australian Family Physician, vol. 39, no. 10, pp. 752–755, 2010. View at: Google Scholar
  46. P. Emadi-Konjin, J. Bain, and I. L. Bromberg, “Evaluation of an algorithm for calculation of serum “Bioavailable” testosterone (BAT),” Clinical Biochemistry, vol. 36, no. 8, pp. 591–596, 2003. View at: Publisher Site | Google Scholar
  47. H. A. Feldman, C. Longcope, C. A. Derby et al., “Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 2, pp. 589–598, 2002. View at: Publisher Site | Google Scholar
  48. M. Maggio, C. Cattabiani, F. Lauretani et al., “The concept of multiple hormonal dysregulation,” Acta Bio-Medica, vol. 81, no. 1, pp. 19–29, 2010. View at: Google Scholar
  49. J. D. Veldhuis, “Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women,” Ageing Research Reviews, vol. 7, no. 3, pp. 189–208, 2008. View at: Publisher Site | Google Scholar
  50. J. D. Veldhuis, “Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis,” Journal of Andrology, vol. 20, no. 1, pp. 1–17, 1999. View at: Publisher Site | Google Scholar
  51. G. P. Ceda, L. Denti, G. Ceresini, W. Torsiglieri, A. R. Hoffman, and G. Valenti, “The effects of aging on the secretion of the common alpha-subunit of the glycoprotein hormones in men,” Journal of the American Geriatrics Society, vol. 39, no. 4, pp. 353–358, 1991. View at: Google Scholar
  52. E.-E. Baulieu, “Androgens and aging men,” Molecular and Cellular Endocrinology, vol. 198, no. 1-2, pp. 41–49, 2002. View at: Publisher Site | Google Scholar
  53. M. T. Haren, M. J. Kim, S. H. Tariq, G. A. Wittert, and J. E. Morley, “Andropause: a quality-of-life issue in older males,” Medical Clinics of North America, vol. 90, no. 5, pp. 1005–1023, 2006. View at: Publisher Site | Google Scholar
  54. K. Krithivas, S. M. Yurgalevitch, B. A. Mohr et al., “Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men,” Journal of Endocrinology, vol. 162, no. 1, pp. 137–142, 1999. View at: Publisher Site | Google Scholar
  55. C. D. Kochakian, “Comparison of protein anabolic property of various androgens in the castrated rat,” American Journal of Physiology, vol. 160, no. 1, pp. 53–61, 1950. View at: Google Scholar
  56. L. Katznelson, J. S. Finkelstein, D. A. Schoenfeld, D. I. Rosenthal, E. J. Anderson, and A. Klibanski, “Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 12, pp. 4358–4365, 1996. View at: Publisher Site | Google Scholar
  57. M. Maggio, F. Lauretani, G. P. Ceda et al., “Association between hormones and metabolic syndrome in older Italian men,” Journal of the American Geriatrics Society, vol. 54, no. 12, pp. 1832–1838, 2006. View at: Publisher Site | Google Scholar
  58. S. Ucak, O. Basat, and G. Karatemiz, “Functional and nutritional state in elderly men with compensated hypogonadism,” Journal of the American Medical Directors Association, vol. 14, no. 6, pp. 433–436, 2013. View at: Publisher Site | Google Scholar
  59. E. Giannetta, D. Gianfrilli, F. Barbagallo, A. M. Isidori, and A. Lenzi, “Subclinical male hypogonadism,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 26, no. 4, pp. 539–550, 2012. View at: Publisher Site | Google Scholar
  60. C. Wang, R. S. Swerdloff, A. Iranmanesh et al., “Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 8, pp. 2839–2853, 2000. View at: Publisher Site | Google Scholar
  61. P. Marin, S. Holmang, C. Gustanoffson et al., “Androgen treatment of abdominally obese men,” Obesity Research & Clinical Practice, vol. 1, no. 4, pp. 245–251, 1993. View at: Google Scholar
  62. S. Bhasin, T. G. Travison, T. W. Storer et al., “Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial,” Journal of the American Medical Association, vol. 307, no. 9, pp. 931–939, 2012. View at: Publisher Site | Google Scholar
  63. M. Sheffield-Moore, E. L. Dillon, S. L. Casperson et al., “A randomized pilot study of monthly cycled testosterone replacement or continuous testosterone replacement versus placebo in older men,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 11, pp. E1831–E1837, 2011. View at: Publisher Site | Google Scholar
  64. S. Bhasin, O. M. Calof, T. W. Storer et al., “Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging,” Nature Clinical Practice. Endocrinology & Metabolism, vol. 2, no. 3, pp. 146–159, 2006. View at: Publisher Site | Google Scholar
  65. T. G. Travison, S. Basaria, T. W. Storer et al., “Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation,” The Journals of Gerontology A, vol. 66, no. 10, pp. 1090–1099, 2011. View at: Publisher Site | Google Scholar
  66. L. Ferrucci, M. Maggio, S. Bandinelli et al., “Low testosterone levels and the risk of anemia in older men and women,” Archives of Internal Medicine, vol. 166, no. 13, pp. 1380–1388, 2006. View at: Publisher Site | Google Scholar
  67. M. Maggio, P. J. Snyder, G. P. Ceda et al., “Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men,” Andrology, vol. 1, no. 1, pp. 24–28, 2013. View at: Publisher Site | Google Scholar
  68. M. Sheffield-Moore, D. Paddon-Jones, S. L. Casperson et al., “Androgen therapy induces muscle protein anabolism in older women,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 10, pp. 3844–3849, 2006. View at: Publisher Site | Google Scholar
  69. X. Xu, G. de Pergola, and P. Bjorntorp, “The effects of androgens on the regulation of lipolysis in adipose precursor cells,” Endocrinology, vol. 126, no. 2, pp. 1229–1234, 1990. View at: Publisher Site | Google Scholar
  70. A. M. Traish and N. Kim, “Weapons of penile smooth muscle destruction: androgen deficiency promotes accumulation of adipocytes in the corpus cavernosum,” The Aging Male, vol. 8, no. 3-4, pp. 141–146, 2005. View at: Publisher Site | Google Scholar
  71. L. R. Brilla and V. Conte, “Effects of a novel zinc-magnesium formulation on hormones and strength,” Journal of Exercise Physiology Online, vol. 3, no. 4, pp. 26–36, 2000. View at: Google Scholar
  72. V. Cinar, Y. Polat, A. K. Baltaci, and R. Mogulkoc, “Effects of magnesium supplementation on testosterone levels of athletes and sedentary subjects at rest and after exhaustion,” Biological Trace Element Research, vol. 140, no. 1, pp. 18–23, 2011. View at: Publisher Site | Google Scholar
  73. A. C. Fry, W. J. Kraemer, and L. T. Ramsey, “Pituitary-adrenal-gonadal responses to high-intensity resistance exercise overtraining,” Journal of Applied Physiology, vol. 85, no. 6, pp. 2352–2359, 1998. View at: Google Scholar
  74. M. Maggio, G. P. Ceda, F. Lauretani et al., “Magnesium and anabolic hormones in older men,” International Journal of Andrology, vol. 34, no. 6, part 2, pp. e594–e600, 2011. View at: Publisher Site | Google Scholar
  75. F. De Vita, F. Lauretani, G. P. Ceda, T. Cederholm, L. Lind, and M. Maggio, “Vitamin D and endothelial vasodilation in older individuals,” in Proceedings of the 7th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD '13), pp. 9–11, Kobe, Japan, December 2013. View at: Google Scholar
  76. A. K. Chandra, P. Sengupta, H. Goswami, and M. Sarkar, “Effects of dietary magnesium on testicular histology, steroidogenesis, spermatogenesis and oxidative stress markers in adult rats,” Indian Journal of Experimental Biology, vol. 51, no. 1, pp. 37–47, 2013. View at: Google Scholar
  77. P. Vernet, A. Britan, E. Gueux, A. Mazur, and J. R. Drevet, “Dietary magnesium depletion does not promote oxidative stress but targets apical cells within the mouse caput epididymidis,” Biochimica et Biophysica Acta, vol. 1675, no. 1–3, pp. 32–45, 2004. View at: Publisher Site | Google Scholar
  78. A. A. Al-Qarawi, H. A. Abdel-Rahman, M. S. El-Belely, and S. A. El-Mougy, “Age-related changes in plasma testosterone concentrations and genital organs content of bulk and trace elements in the male dromedary camel,” Animal Reproduction Science, vol. 62, no. 4, pp. 297–307, 2000. View at: Publisher Site | Google Scholar
  79. D. I. Spratt, P. Cox, J. Orav, J. Moloney, and T. Bigos, “Reproductive axis suppression in acute illness is related to disease severity,” The Journal of Clinical Endocrinology & Metabolism, vol. 76, no. 6, pp. 1548–1554, 1993. View at: Publisher Site | Google Scholar
  80. M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci, “Interleukin-6 in aging and chronic disease: a magnificent pathway,” The Journals of Gerontology A, vol. 61, no. 6, pp. 575–584, 2006. View at: Google Scholar
  81. S. Stenholm, M. Maggio, F. Lauretani et al., “Anabolic and catabolic biomarkers as predictors of muscle strength decline: the InCHIANTI study,” Rejuvenation Research, vol. 13, no. 1, pp. 3–11, 2010. View at: Publisher Site | Google Scholar
  82. L. A. Schaap, S. M. F. Pluijm, D. J. H. Deeg, and M. Visser, “Inflammatory markers and loss of muscle mass (Sarcopenia) and strength,” The American Journal of Medicine, vol. 119, no. 6, pp. 526.e9–526.e17, 2006. View at: Publisher Site | Google Scholar
  83. M. Maggio, G. P. Ceda, G. de Cicco et al., “Acute changes in circulating hormones in older patients with impaired ventricular function undergoing on-pump coronary artery bypass grafting,” Journal of Endocrinological Investigation, vol. 28, no. 8, pp. 711–719, 2005. View at: Google Scholar
  84. C. J. Malkin, P. J. Pugh, R. D. Jones, D. Kapoor, K. S. Channer, and T. H. Jones, “The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 7, pp. 3313–3318, 2004. View at: Publisher Site | Google Scholar
  85. S. M. Liva and R. R. Voskuhl, “Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production,” The Journal of Immunology, vol. 167, no. 4, pp. 2060–2067, 2001. View at: Google Scholar
  86. B. F. Dickens, W. B. Weglicki, Y.-S. Li, and I. T. Mak, “Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells,” FEBS Letters, vol. 311, no. 3, pp. 187–191, 1992. View at: Publisher Site | Google Scholar
  87. J. Liu, E. Head, A. M. Gharib et al., “Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-α-lipoic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 4, pp. 2356–2361, 2002. View at: Publisher Site | Google Scholar
  88. K. R. Short, M. L. Bigelow, J. Kahl et al., “Decline in skeletal muscle mitochondrial function with aging in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 15, pp. 5618–5623, 2005. View at: Publisher Site | Google Scholar
  89. Y. Rayssiguier, J. Durlach, E. Gueux, E. Rock, and A. Mazur, “Magnesium and ageing—I. Experimental data: importance of oxidative damage,” Magnesium Research, vol. 6, no. 4, pp. 369–378, 1993. View at: Google Scholar
  90. Y. Yang, Z. Wu, Y. Chen et al., “Magnesium deficiency enhances hydrogen peroxide production and oxidative damage in chick embryo hepatocyte in vitro,” BioMetals, vol. 19, no. 1, pp. 71–81, 2006. View at: Publisher Site | Google Scholar
  91. C. Franceschi, M. Bonafè, S. Valensin et al., “Inflamm-aging: an evolutionary perspective on immunosenescence,” Annals of the New York Academy of Sciences, vol. 908, pp. 244–254, 2000. View at: Publisher Site | Google Scholar
  92. L. Excoffon, Y. C. Guillaume, M. C. Woronoff-Lemsi, and C. André, “Magnesium effect on testosterone-SHBG association studied by a novel molecular chromatography approach,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 2, pp. 175–180, 2009. View at: Publisher Site | Google Scholar
  93. M. Maggio, G. P. Ceda, F. Lauretani et al., “SHBG, sex hormones, and inflammatory markers in older women,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 4, pp. 1053–1059, 2011. View at: Publisher Site | Google Scholar
  94. G. V. Avvakumov, I. Grishkovskaya, Y. A. Muller, and G. L. Hammond, “Crystal structure of human sex hormone-binding globulin in complex with 2-methoxyestradiol reveals the molecular basis for high affinity interactions with C-2 derivatives of estradiol,” The Journal of Biological Chemistry, vol. 277, no. 47, pp. 45219–45225, 2002. View at: Publisher Site | Google Scholar
  95. G. V. Avvakumov, Y. A. Muller, and G. L. Hammond, “Steroid-binding specificity of human sex hormone-binding globulin is influenced by occupancy of a zinc-binding site,” The Journal of Biological Chemistry, vol. 275, no. 34, pp. 25920–25925, 2000. View at: Publisher Site | Google Scholar
  96. C. André, A. Xicluna, J.-F. Robert, M. Thomassin, and Y.-C. Guillaume, “Reanalysis of the testosterone displacement from its HSA binding site by DHEA using competitive Langmuir isotherm,” Talanta, vol. 65, no. 3, pp. 814–818, 2005. View at: Publisher Site | Google Scholar
  97. C. André, A. Berthelot, J. F. Robert, M. Thomassin, and Y. C. Guillaume, “Testimony of the correlation between DHEA and bioavailable testosterone using a biochromatographic concept: effect of two salts,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 5, pp. 911–921, 2003. View at: Publisher Site | Google Scholar

Copyright © 2014 Marcello Maggio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles